GUARNERI, Valentina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.265
EU - Europa 8.818
AS - Asia 8.724
SA - Sud America 1.296
Continente sconosciuto - Info sul continente non disponibili 252
AF - Africa 211
OC - Oceania 16
Totale 38.582
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.869
IT - Italia 2.672
SG - Singapore 2.619
CN - Cina 2.221
GB - Regno Unito 1.925
HK - Hong Kong 1.062
BR - Brasile 979
IE - Irlanda 863
VN - Vietnam 816
SE - Svezia 745
DE - Germania 622
BD - Bangladesh 588
FI - Finlandia 412
UA - Ucraina 401
RU - Federazione Russa 303
FR - Francia 287
TR - Turchia 246
KR - Corea 242
IN - India 234
CA - Canada 211
BG - Bulgaria 146
ID - Indonesia 141
AR - Argentina 101
NL - Olanda 94
MX - Messico 84
JP - Giappone 83
IQ - Iraq 69
ES - Italia 56
ZA - Sudafrica 56
PL - Polonia 55
CO - Colombia 50
PK - Pakistan 46
AE - Emirati Arabi Uniti 45
EC - Ecuador 41
PH - Filippine 40
VE - Venezuela 36
CL - Cile 34
LT - Lituania 33
MY - Malesia 32
BE - Belgio 30
UZ - Uzbekistan 28
CR - Costa Rica 25
AT - Austria 24
MA - Marocco 24
PY - Paraguay 24
SA - Arabia Saudita 24
EG - Egitto 23
IR - Iran 20
JO - Giordania 19
TW - Taiwan 19
JM - Giamaica 18
CZ - Repubblica Ceca 17
HU - Ungheria 16
TH - Thailandia 16
AU - Australia 15
ET - Etiopia 15
GR - Grecia 15
KE - Kenya 15
AZ - Azerbaigian 14
CH - Svizzera 14
TN - Tunisia 14
DZ - Algeria 13
AL - Albania 12
BO - Bolivia 12
NG - Nigeria 12
PT - Portogallo 12
DO - Repubblica Dominicana 11
KZ - Kazakistan 11
LB - Libano 11
OM - Oman 11
HN - Honduras 10
NP - Nepal 10
RO - Romania 10
RS - Serbia 8
SN - Senegal 8
UY - Uruguay 8
EU - Europa 7
IL - Israele 7
PA - Panama 7
PE - Perù 7
QA - Qatar 7
SC - Seychelles 7
CI - Costa d'Avorio 6
CY - Cipro 6
MD - Moldavia 6
SI - Slovenia 6
SY - Repubblica araba siriana 6
LV - Lettonia 5
MK - Macedonia 5
TT - Trinidad e Tobago 5
BA - Bosnia-Erzegovina 4
BH - Bahrain 4
DK - Danimarca 4
KW - Kuwait 4
LA - Repubblica Popolare Democratica del Laos 4
NI - Nicaragua 4
PR - Porto Rico 4
AO - Angola 3
AP - ???statistics.table.value.countryCode.AP??? 3
BB - Barbados 3
Totale 38.271
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.818
Ashburn 1.757
Singapore 1.742
Fairfield 1.457
Southend 1.136
Woodbridge 1.095
Hong Kong 1.041
Chandler 916
Houston 891
Dublin 861
San Jose 841
Jacksonville 736
Dearborn 622
Ann Arbor 582
Council Bluffs 556
Seattle 548
Wilmington 518
Beijing 517
Hefei 509
Cambridge 485
Nyköping 434
London 381
Los Angeles 358
New York 315
Chicago 290
The Dalles 278
Milan 271
Helsinki 266
Ho Chi Minh City 250
Modena 228
Seoul 210
Hanoi 200
Rome 181
San Diego 167
Princeton 156
Sofia 139
Eugene 131
Lauterbourg 131
Columbus 128
Izmir 126
Buffalo 120
Moscow 113
Dallas 109
Jakarta 104
Munich 103
Salt Lake City 101
Shanghai 101
São Paulo 84
Naples 79
Boardman 63
Bologna 59
Des Moines 59
Falls Church 58
Frankfurt am Main 57
Tokyo 55
Phoenix 54
Elk Grove Village 52
Orem 51
Atlanta 49
Toronto 49
Turin 49
Tampa 48
Florence 45
Da Nang 43
Bari 42
Dong Ket 41
Norwalk 40
Bremen 37
Denver 37
Haiphong 37
Redwood City 35
Warsaw 34
Chennai 32
Guangzhou 32
Fremont 31
Palermo 31
Mexico City 29
Montreal 29
Genoa 28
Mumbai 28
Redondo Beach 28
Brooklyn 27
Rio de Janeiro 27
Turku 27
Nanjing 26
Boston 25
Tashkent 25
Brussels 24
Catania 24
Curitiba 24
Kunming 24
Miano 24
San Mateo 24
Amsterdam 23
Charlotte 23
Kent 23
Nuremberg 23
Verona 23
Ottawa 22
Stockholm 22
Totale 26.004
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.173
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 498
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 435
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 435
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 422
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 407
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 394
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 391
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 386
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 384
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 382
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici 376
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 367
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 362
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 358
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 356
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 344
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas 341
Achievements and unmet needs in the management of advanced ovarian cancer 335
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 332
Long term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience 330
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 326
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 326
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 325
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 323
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 321
Detection of microparticles from human red blood cells by multiparametric flow cytometry 320
Immune characterization of breast cancer metastases: prognostic implications. 315
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 315
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 314
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors 314
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 313
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 311
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 309
Trastuzumab containing regimens for early breast cancer. 305
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 303
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 302
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 301
Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer 299
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 284
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 281
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 279
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 278
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 277
The curability of breast cancer and the treatment of advanced disease 274
Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. 273
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 272
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 271
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 270
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 270
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 269
P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 264
Downregulation of the Cyclin-Dependent Kinase Inhibitor p27kip1 Might Correlate with Poor Disease-Free and Overall Survival in Inflammatory Breast Cancer 263
Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. 262
Biomarkers predicting clinical benefit: fact or fiction? 259
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 257
Biomarker expression and survival after primary chemotherapy for breast cancer. 257
Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials 255
Use of Ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients. 254
CHER-LOB: PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB, LAPATINIB OR BOTH IN HER2-POSITIVE OPERABLE BREAST CANCER – PRELIMINARY SAFETY REPORT WITH FOCUS ON CARDIAC TOLERABILITY 253
Primary Systemic Therapy in operable breast cancer: clinical data and biological fall-out 251
Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial. 251
Timing for starting second-line therapy in recurrent ovarian cancer 249
Discordant HER2 Total and HER2 Homodimer Levels by HERmark Analysis in Matched Primary and Metastatic Breast Cancer FFPE Specimens. 248
Pazopanib-Induced Heart Failure In A Metastastic Sarcoma Patient: Between Reversible Side Effect and Efficacy 246
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2þ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. 246
Bone metastases- Pharmacological treatment 245
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS 245
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 245
KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 242
Adding weekly carboplatin to sequential anthracycline and paclitaxel-based chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC) patients: a propensity scorematched study 241
Tumori ginecologici 241
High – dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study 241
Trastuzumab-containing regimens for metastatic breast cancer 238
Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. 236
Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+ breast cancer 232
Bevacizumab treatment for advanced breast cancer. 232
Safety of intravenous and oral bisphosphonates and compliance with dosing regimens 231
Changes in survival and time to progression in metastatic breast cancer (MBC) patients enrolled into clinical trials from 1983 to 2001 231
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support 230
In response to Body letter to the editor regarding "Safety of intravenous and oral Bisphosphonates and compliance with dosing regimens" 230
Weekly docetaxel/paclitaxel in pretreated metalistic breast cancer 230
Triple-negative breast cancer: current management and future options. 227
Renal safety and efficacy of intravenous bisphosphonates in patients with skeletal metastases treated for up to ten years 226
LET-LOB: preoperative letrozole plus lapatinib or placebo in hormone-receptor positive HER2 negative operable breats cancer. Preliminary report of activity and cardiac tolerability 225
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVE: ANALISI PRELIMINARE DELLE TOSSICITA’ 224
LAPATINIB IN ASSOCIAZIONE A CAPECITABINA IN PAZIENTI CON CARCINOMA MAMMARIO METASTTICO HER2 POSITIVO IN PROGRESSIONE DOPO TERAPIA CON TRASTUZUMAB 223
Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives 223
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact 216
Pattern of distant relapse according to intrinsic molecular subtype in patients with HER2-positive breast cancer: a combined analysis of ShortHER, CherLOB, and two institutional cohorts 215
The Next Generation of Biologic Agents: Therapeutic Role in Relation to Existing Therapies in Metastatic Breast Cancer 215
Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden 214
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation 213
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial 213
In response to Jackson letter to the editor regarding "Safety of intravenous and oral bisphosphonates and compliance with dosing regimens" 211
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 210
Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial. 209
CARCINOMI MAMMARI HER2 POSITIVI: CASISTICA DI MODENA 208
Operable Breast Cancer: preliminary results of a phase II, double blind, placebo controlled, randomized trial of preoperative chemotherapy +/- gefitinib with biomarkers evaluation 208
Lapatinib or placebo plus letrozole as preoperative treatment of hormone receptor-positive HER2-negative operable breast cancer. Preliminary report of safety and activity of the double-blind randomized phase IIb LET-LOB study 207
Totale 29.240
Salva come PNG Salva come JPEG
Categoria #
all - tutte 142.999
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 142.999
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.022 0 0 288 108 64 135 149 119 278 202 394 285
2022/20233.462 331 307 174 248 282 375 52 248 1.156 48 137 104
2023/20242.185 98 131 120 134 324 172 169 437 75 115 161 249
2024/20256.106 185 117 106 483 1.214 1.089 323 387 673 314 488 727
2025/202612.607 705 405 882 1.326 1.982 838 1.514 646 1.136 1.243 1.075 855
2026/20271.618 584 904 130 0 0 0 0 0 0 0 0 0
Totale 38.582